Gossamer Bio reports 2025 net loss $170.4M; seralutinib Phase 3 narrowly missed primary endpoint

Gossamer Bio, Inc.

PROSERA Phase 3 in PAH showed placebo-adjusted 6MWD +13.3 meters but missed prespecified statistical alpha of 0.025 (p=0.0320).
Enrollment in Phase 3 SERANATA (PH-ILD) paused; Company evaluating implications and plans FDA Type C meeting in June 2026.
Implemented reduction in force and cost-containment measures to align resources with near-term priorities.
Cash, equivalents and marketable securities $136.9M at Dec 31, 2025; expected to fund operations into Q1 2027.
Net loss for FY2025 was $170.4M ($0.75 per share) compared to $56.5M ($0.25 per share) in FY2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Gossamer Bio, Inc. reported the quarter and fiscal year ended December 31, 2025 results: net income Net loss for the three months ended December 31, 2025, was $47.2 million, or $0.21 per share, compared to a net loss of, EPS Net loss for the three months ended December 31, 2025, was $47.2 million, or $0.21 per share, compared to a net loss of.

Period: the quarter and fiscal year ended December 31, 2025
Net income: Net loss for the three months ended December 31, 2025, was $47.2 million, or $0.21 per share, compared to a net loss of
EPS: Net loss for the three months ended December 31, 2025, was $47.2 million, or $0.21 per share, compared to a net loss of
Result: reported results

Exact text from the filing

On March 17, 2026 , Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter and fiscal year ended December 31, 2025.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Gossamer Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001728117-26-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.